Akari Therapeutics, Plc, an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, ...
ADC Contract Manufacturing Market, 2035 - Surging Demand for Antibody Drug Conjugates Driving Growth
Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "ADC Contract Manufacturing Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Stage of Development, Process Component, Target ...
TAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology ...
Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "ADC Contract Manufacturing Market Industry Trends and Global Forecasts to 2035, by Stage of Development, Process Component, Target Indication, Antibody ...
Antibody drug conjugates have fast become a big piece of AstraZeneca’s revenue growth. The drugmaker is taking steps to ensure it has the production capacity to meet market demand for these cancer ...
14 May 2018, Wales: ADC Biotechnology (ADC Bio), together with Maven Capital Partners and Bioscience Managers, is to host a webinar through ADC Review entitled ‘Investing for the future: unlocking ...
Lonza to Expand Antibody Drug Conjugate (ADC) Manufacturing Capacity to Meet Growing Customer Demand
Basel, Switzerland, 8 January 2013 – Lonza today announced plans to invest CHF 14 million to expand Antibody Drug Conjugate (ADC) manufacturing capacity in Visp, Switzerland. Oncology therapeutics ...
DUBLIN--(BUSINESS WIRE)--The "ADC Contract Manufacturing Market (3rd Edition), 2018-2030" report has been added to ResearchAndMarkets.com's offering. The ADC Contract Manufacturing Market (3rd edition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback